Royce & Associates LP Purchases 39,685 Shares of Prestige Consumer Healthcare Inc. $PBH

Royce & Associates LP raised its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 68.3% in the 4th quarter, Holdings Channel reports. The firm owned 97,750 shares of the company’s stock after buying an additional 39,685 shares during the quarter. Royce & Associates LP’s holdings in Prestige Consumer Healthcare were worth $6,030,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Bayforest Capital Ltd bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth $29,000. Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in shares of Prestige Consumer Healthcare by 106.8% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after acquiring an additional 283 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares during the last quarter. Torren Management LLC bought a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth $35,000. Finally, Danske Bank A S bought a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth $37,000. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock opened at $47.53 on Friday. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $2.25 billion, a PE ratio of 12.15, a P/E/G ratio of 1.56 and a beta of 0.40. The firm has a fifty day simple moving average of $54.63 and a two-hundred day simple moving average of $60.46. Prestige Consumer Healthcare Inc. has a twelve month low of $42.62 and a twelve month high of $87.12.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). The business had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business’s revenue for the quarter was down 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on PBH shares. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Jefferies Financial Group dropped their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Canaccord Genuity Group dropped their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Finally, Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Hold” and a consensus target price of $70.75.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president directly owned 42,820 shares of the company’s stock, valued at $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.40% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).